Wednesday, June 19, 2013 Last update: 9:45 AM
Company Tech News as it Breaks
Trade Events
Navidea Biopharmaceuticals, Inc.
News articles for Navidea Biopharmaceuticals, Inc.:
Wednesday, June 12, 2013
- Navidea Biopharmaceuticals Announces Presentation of Meta-Analysis Results of Lymphoseek® and ACOSOG Radiolabeled Colloid in Head and Neck CancerNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results from a meta-analysis study of Lymphoseek® (technetium ... read more
Tuesday, June 11, 2013
- Navidea Biopharmaceuticals Announces Results from Lymphoseek® Study on Accuracy of Lymph Node Detection from Injection Time to SurgeryNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced positive results from a meta-analysis study of Lymphoseek® ... read more
Monday, June 10, 2013
- Navidea Biopharmaceuticals Announces Presentation of Results from Two Lymphoseek® and Radiolabeled Colloid Studies in Lymphatic Mapping for Breast Cancer at SNMMINavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results from two separate studies that compared the ... read more
Wednesday, May 29, 2013
- Navidea Biopharmaceuticals Announces Highlights of Lymphoseek® Data Presented at Joint International Oncology Congress (JIOC)Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced highlights of data from its Lymphoseek® (technetium ... read moreNavidea Biopharmaceuticals to Present at the Jefferies 2013 Global Healthcare ConferenceNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Thomas Tulip, President and Chief Business Officer, will ... read more
Wednesday, May 22, 2013
- Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Joint International Oncology Congress (JIOC)Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek® (technetium Tc 99m ... read more
Wednesday, May 15, 2013
- Navidea Biopharmaceuticals Signs Manufacturing and Supply Agreement with NordionNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has entered into an agreement with Nordion (Canada) ... read more
Wednesday, May 8, 2013
- Navidea Biopharmaceuticals Announces First Quarter 2013 ResultsNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced business highlights and consolidated results for the first ... read more
Friday, May 3, 2013
- Navidea Biopharmaceuticals to Announce First Quarter 2013 Financial Results Pre-market on Wednesday, May 8, 2013Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the ... read more
Wednesday, May 1, 2013
- Navidea Biopharmaceuticals Announces the U.S. Launch of Lymphoseek®Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced the U.S. launch of Lymphoseek® ... read more
Wednesday, April 24, 2013
- Navidea Biopharmaceuticals Announces Underwritten Sale of Common StockNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has priced an underwritten sale of common stock in a ... read more
Thursday, April 18, 2013
- Navidea Biopharmaceuticals Announces that Results of NAV4694 Clinical Trial Published in the Journal of Nuclear MedicineNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the peer-reviewed publication of results from a clinical trial ... read more
Thursday, April 11, 2013
- Navidea's Presentation of Top-Line Interim Analysis of Lymphoseek® Head and Neck Phase 3 Trial Selected for Investigator AwardNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that a presentation of results from its Phase 3 clinical trial ... read more
Friday, April 5, 2013
- Navidea Biopharmaceuticals Retains Stern IR for Investor Relations ServicesNavidea Biopharmaceuticals (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has retained Stern Investor Relations, Inc. to provide strategic ... read more
Thursday, April 4, 2013
- Navidea Biopharmaceuticals Announces Positive Top-Line Results from Interim Analysis of Lymphoseek® Phase 3 Clinical Trial in Head and Neck CancerNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced top-line results from ... read more
Wednesday, April 3, 2013
- Navidea and Collaborator Molecular Neuroimaging Enroll First Subject in NAV5001 Clinical TrialNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators at Molecular Neuroimaging, LLC (MNI) in New ... read more
Monday, April 1, 2013
- Navidea Biopharmaceuticals to Present at the Future Leaders in the Biotech Industry ConferenceNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, Navidea’s President and Chief Executive ... read more
Wednesday, March 27, 2013
- Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI)Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced in its Phase 2b, open-label, ... read more
Thursday, March 21, 2013
- Results of Lymphoseek® Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical OncologyNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced the peer-reviewed ... read more
Wednesday, March 13, 2013
- Navidea Biopharmaceuticals to Hold Conference Call to Discuss Lymphoseek FDA ApprovalNavidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, will hold a conference call at 4:00 p.m. EDT today to discuss the U.S. ... read more